Actively Recruiting
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
Led by The First Affiliated Hospital of Guangzhou Medical University · Updated on 2025-02-25
2500
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.
CONDITIONS
Official Title
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signing of the informed consent form
- Male or female, aged 18-75 years
- Patients with lung nodules confirmed by CT examination
- Good preoperative pulmonary function cooperation and complete reporting
- Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging
- The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month
You will not qualify if you...
- Poor preoperative pulmonary function cooperation or missing reports
- Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission
- The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month
- Complication with severe respiratory disorders such as lung transplantation, pneumothorax, or giant bullae
- Coexisting with other severe functional impairments
- Patients with obstructive lesions such as airway or esophageal stenosis
- Medication use before pulmonary function testing that does not meet cessation guidelines
- Pulmonary function report quality graded D-F
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the First Affiliated of Guangzhou Medical University
Guangzhou, Guangdong, China, 510120
Actively Recruiting
Research Team
J
Jianxing He, Professer
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here